摘要
目的观察卡维地洛对缺血性心肌病伴心房颤动疗效、安全性、对患者脑钠素(BNP)浓度的影响及与心力衰竭预后的关系。方法86例缺血性心肌病伴心房颤动患者随机分为常规治疗组42例和常规治疗基础上加用卡维地洛(卡维地洛组)44例。测定两组患者治疗前、治疗2周后BNP浓度及心功能,观察卡维地洛对心功能及BNP浓度的影响;以6个月内再入院或死亡作为观察终点,评价卡维地洛对心力衰竭预后的影响。结果治疗后卡维地洛组与常规治疗组均有BNP浓度下降,卡维地洛组BNP浓度下降更明显(P<0.05);卡维地洛组5例发生终点事件,发生率11.4%,常规治疗组20例发生终点事件,发生率47.6%,常规治疗组终点事件发生率高(P<0.01),所有终点事件发生者BNP>700pg/ml。结论卡维地洛可以改善缺血性心肌病伴心房颤动患者心功能及预后;BNP>700pg/ml可以预测缺血性心肌病伴心房颤动患者预后。
Objective To observe effects of carvedilol on the changes of B-type natriuretic peptide （BNP） concentration in ischemic cardiomyopathy （ICM） patients and on the prognosis of these patients. Methods 86 patients admitted for ischemic cardiomyopathy with atria fibrillation and BNP concentration before and after treatment were followed. The subjects were divided into two groups based on with or without carvedilol. Carvedilol group included 44 cases , another group included 42 cases. Endpoints was death or 6 month readmission. Results BNP levels decreased more in cardevilol group（ P〈0. 05 ） ; there were 5 endpoint events in carvedilol group （ 11.4 % ）, 20 endpoint events in another group （ 47.6 % ）, the ratio of endpoint events was significant different in two groups（ P 〈 0. 01 ）. BNP level of endpoint events was over 700 pg/rnl. Conclusion Carvedilol can decrease BNP level and improve prognosis in patients with chronic .heart failure, patients admit ted for ischemic cardiomyopathy, after treatment BNP level 〉700pg/ml can predict prognosis.
出处
《中国心血管杂志》
2006年第6期436-438,共3页
Chinese Journal of Cardiovascular Medicine
关键词
缺血性心肌病
心房颤动
卡维地洛
脑钠素
Ischemic cardiomyopathy
Atria fibrillation
Carvedilol
B-type natriureticpeptide
